Vac­cines – Ther­a­peu­tics – Anti Micro­bial Pep­tides

Accord­ing to the US FDA, antimi­cro­bial resis­tance is rec­og­nized as a grow­ing glob­al threat. Via hor­i­zon­tal gene trans­fer, antibi­ot­ic resis­tance genes may be trans­ferred to humans, there­by reduc­ing the effec­tive­ness of antimi­cro­bial drugs for treat­ing human dis­ease.

ARTES´ pro­vides access to its pro­pri­etary yeast tech­nol­o­gy plat­form com­plete­ly void of any antibi­ot­ic resis­tance mark­er through­out the full man­u­fac­tur­ing process of vet­eri­nary prod­ucts, such as vac­cines, ther­a­peu­tic pro­teins and anti micro­bial pep­tides. Togeth­er with aller­gen and tox­in free pro­duc­tion cell lines, ARTES ensures safe vet­eri­nary prod­ucts.

The METAVAX® tech­nol­o­gy plat­form is ide­al­ly suit­ed for devel­op­ment of vet­eri­nary vac­cines by pre­sen­ta­tion of tar­get anti­gens in form of chimeric virus like par­ti­cles (VLPs). This approach is a.o. rec­og­nized by the EU, fund­ing the devel­op­ment of nov­el METAVAX® based vet­eri­nary vac­cines (Pluri­vax).